Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 392 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Double-S Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

NCT03119649
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
GLPG2222 50 mg, GLPG2222 100 mg, Placebo, GLPG2222 200 mg, GLPG2222 400 mg
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 99 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
7
States / cities
Chatom, Alabama • Little Rock, Arkansas • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 28, 2026, 5:35 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Not listed Not applicable Interventional

Treatment of Tinnitus With Noninvasive Neuromodulation and Listening Therapy

NCT04934371
View directory record Official record
Conditions
Tinnitus, Subjective, Hyperacusis, Hearing Disorders
Interventions
Transcranial Direct Current Stimulation (tDCS), Sham TDCS
Device
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 28, 2026, 5:35 PM EDT
Completed No phase listed Observational

Brain Imaging in Men With Lower Urinary Tract Symptoms

NCT03991429
View directory record Official record
Conditions
Voiding Disorders
Interventions
Simultaneous functional MRI and urodynamic studies, Questionnaires, Post Void Residual (PVR), Uroflow and Bladder Diary, Urinalysis
Diagnostic Test · Behavioral · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 90 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 1 Interventional

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

NCT03880357
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Betamethasone Scalp Suspension 0.064%;0.0005%, Taclonex®, Placebo topical suspension
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy

NCT01755767
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tivantinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

NCT03337477
View directory record Official record
Conditions
Hyperkalemia
Interventions
Placebo, Sodium Zirconium Cyclosilicate(ZS), Insulin, Glucose
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Montgomery, Alabama • Phoenix, Arizona • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Not applicable Interventional Results available

Percutaneous Electrical Nerve Field Stimulation for Adults With Irritable Bowel Syndrome

NCT04428619
View directory record Official record
Conditions
Irritable Bowel Syndrome, Abdominal Pain, Autonomic Nervous System Imbalance
Interventions
Peripheral Electrical Nerve Field Stimulation (PENFS) Device, Sham Device
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

NCT04777409
View directory record Official record
Conditions
Early Alzheimer´s Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

NCT01153347
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
79
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

NCT05047601
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332, Placebo for PF-07321332, Placebo for Ritonavir, Ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
64
States / cities
Pelham, Alabama • Tucson, Arizona • Fullerton, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1

NCT04481035
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-acetylcysteine (NAC), Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis

NCT05660382
View directory record Official record
Conditions
Otomycosis
Interventions
Miconazole (2%) oil and mineral oil, Placebo
Drug · Other
Lead sponsor
Hill Dermaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Chula Vista, California • Louisville, Kentucky • North Charleston, South Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Terminated Phase 2Phase 3 Interventional

Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT02341560
View directory record Official record
Conditions
Non Arteritic Anterior Ischemic Optic Neuropathy
Interventions
QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg, Sham Injection Procedure
Drug · Other
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
44
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

NCT00085735
View directory record Official record
Conditions
Medulloblastoma
Interventions
Cisplatin, Craniospinal Irradiation, Cyclophosphamide, Involved-Field Radiation Therapy, Laboratory Biomarker Analysis, Lomustine, Quality-of-Life Assessment, Radiation Therapy, Vincristine Sulfate
Drug · Radiation · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
174
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Active, not recruiting No phase listed Observational

Registry of the Patient Experience for Carpal Tunnel Release

NCT06071468
View directory record Official record
Conditions
Carpal Tunnel Syndrome, CTS
Interventions
UltraGuideCTR (Device) with Ultrasound Guided Carpal Tunnel Release (CTR-US), Endocscopic CTR, Open CTR
Device · Procedure
Lead sponsor
Sonex Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,424 participants
Timeline
2024 – 2027
U.S. locations
33
States / cities
Foley, Alabama • Scottsdale, Arizona • Glastonbury, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

NCT00962390
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
S-equol, Placebo
Drug
Lead sponsor
Ausio Pharmaceuticals, LLC
Industry
Eligibility
50 Years and older · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Huntsville, Alabama • Aventura, Florida • Clearwater, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 28, 2026, 5:35 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

NCT06243835
View directory record Official record
Conditions
Chronic Pain
Interventions
Kindolor Tosylate, Placebo
Drug
Lead sponsor
Lohocla Research Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)

NCT01589185
View directory record Official record
Conditions
Pneumonia Due to Staphylococcus Aureus
Interventions
KBSA301, Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

NCT03615326
View directory record Official record
Conditions
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Monterey, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cortical Activation and Cognitive-Motor Learning

NCT04666181
View directory record Official record
Conditions
Dual-task, Healthy Adults
Interventions
Dual-task training
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects

NCT02876796
View directory record Official record
Conditions
PD Effects of GS-0976 (NDI-010976) on Fractional DNL
Interventions
GS-0976, Placebo, 1-13C acetate, Fructose solution
Drug · Other
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 28, 2026, 5:35 PM EDT
Not listed Phase 2 Interventional

PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health

NCT06186531
View directory record Official record
Conditions
Menopause, Hot Flashes
Interventions
PhytoSERM, Placebo
Dietary Supplement · Drug
Lead sponsor
NeuTherapeutics
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 28, 2026, 5:35 PM EDT